用于治疗多发性硬化症和肠道微生物群的疾病修饰疗法:系统审查
Chia-Chen Tsai1,2, Sophia Jette1, Helen Tremlett3
1Division of Neurology, Faculty of Medicine, Djavad Mowafaghian Centre for Brain Health, Room S126, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC, V6T 2B5, Canada.
Journal of neurology
|December 11, 2023
概括
多发性硬化症 (MS) 的疾病修饰疗法 (DMT) 并没有改变肠道微生物群的多样性. 然而,特定的肠道细菌和功能途径在DMT暴露和未暴露的MS患者 (pwMS) 之间有所不同.
科学领域:
- 微生物学 微生物学
- 神经免疫学 神经免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肠道微生物组在多发性硬化症 (MS) 中的作用越来越被认可,但其与疾病修饰疗法 (DMT) 的相互作用仍然不太清楚.
- 本系统性审查研究了DMT使用与患有多发性硬化症 (pwMS) 人的肠道微生物群组成和功能之间的关系.
研究的目的:
- 系统地审查和综合有关DMT与pwMS肠道微生物群之间的关系的现有文献.
- 检查DMT暴露和未暴露的pWMS之间的肠道微生物群多样性,分类学组成和功能能力的差异.
主要方法:
- 从2007年1月到2022年9月,在主要数据库 (MEDLINE,EMBASE,Web of Science,Scopus) 进行了系统的文献搜索.
- 包括比较DMT暴露与未暴露的pWMS肠道微生物群的研究,或DMT启动前与后的研究.
- 考虑了所有美国FDA批准的MS DMT和rituximab.
主要成果:
- 包括11项涉及1243个pwMS的研究;821个暴露于DMT,473个未暴露.
- 在暴露于DMT和未暴露的组之间,没有发现肠道微生物群α多样性的显著差异.
- 观察到分类基层的差异,特定的属 (例如,Bacteroides,Pseudomonas) 和一种物种 (Ruthenibacterium lactatiformans) 显示出改变的丰度. 使用DMT的人在碳水化合物降解和减少三酸循环途径中表现出较低的相对丰度.
结论:
- 在MS中使用DMT与整体肠道微生物群多样性的变化无关.
- 在DMT暴露和未暴露的pWMS之间存在肠道微生物群的分类水平和功能差异.
- 由于大多数研究的横截面性质和对各种DMT的综合分析,需要进行进一步的研究.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
129
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
129
Chronic Bowel Disorders: Introduction
456
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
456
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Irritable Bowel Syndrome I: Introduction
279
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
279
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
335
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
335


